The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type ​2 diabetes, the drugmaker said on Thursday, offering patients ‌an alternative to ...

Approval marks the second once-weekly basal insulin for this population ...

The FDA approved Onswik, a once-weekly basal insulin for adults with type 2 diabetes. Here's how it works, who it's for and ...

Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora ...

Dr. Marie McDonnell, the director of the Brigham Diabetes Program at Brigham and Women’s Hospital in Boston, told TODAY that basal insulin is a long-acting insulin therapy that helps the body process ...

Eli Lilly and Company LLY secured FDA approval for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin to treat ...

Please provide your email address to receive an email when new articles are posted on . Change in HbA1c and hypoglycemia rates were similar between once-weekly basal insulin and once-daily insulin ...

Dexcom said Smart Basal works to dial in a personalized background insulin dose by checking all of a user's CGM readings, not a fasting blood sugar check. (Dexcom) Dexcom has obtained an FDA clearance ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the ...

Hypoglycemia after basal insulin initiation is associated with high clinical and economic burden that precedes insulin initiation and persists during 1 to 2 years of follow-up. Objectives: To assess ...

SAN DIEGO – The investigational once-weekly insulin icodec provided superior glucose control compared with the once-daily basal insulins degludec and glargine in type 2 diabetes, results from two new ...